Showing 121 - 140 results of 153 for search '"Pfizer"', query time: 0.06s Refine Results
  1. 121

    Impact of COVID-19 vaccination on tinnitus onset and severity: a comprehensive survey study by Anusha Yellamsetty, Egbe-Etu Etu, Shaowen Bao

    Published 2025-02-01
    “…There was no significant difference in tinnitus onset latency between mRNA vaccines (Pfizer and Moderna) and non-mRNA vaccines (Johnson & Johnson). …”
    Get full text
    Article
  2. 122
  3. 123

    Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost by Bo Zhang, Youyi Fong, Lauren Dang, Jonathan Fintzi, Shiyu Chen, Jing Wang, Nadine G. Rouphael, Angela R. Branche, David J. Diemert, Ann R. Falsey, Daniel S. Graciaa, Lindsey R. Baden, Sharon E. Frey, Jennifer A. Whitaker, Susan J. Little, Satoshi Kamidani, Emmanuel B. Walter, Richard M. Novak, Richard Rupp, Lisa A. Jackson, Chenchen Yu, Craig A. Magaret, Cindy Molitor, Bhavesh Borate, Sydney Busch, David Benkeser, Antonia Netzl, Derek J. Smith, Tara M. Babu, Angelica C. Kottkamp, Anne F. Luetkemeyer, Lilly C. Immergluck, Rachel M. Presti, Martín Bäcker, Patricia L. Winokur, Siham M. Mahgoub, Paul A. Goepfert, Dahlene N. Fusco, Robert L. Atmar, Christine M. Posavad, Jinjian Mu, Mat Makowski, Mamodikoe K. Makhene, Seema U. Nayak, Paul C. Roberts, Peter B. Gilbert, Dean Follmann, Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team

    Published 2025-01-01
    “…For 985 recipients of an mRNA second bivalent or monovalent booster containing various Spike inserts [Prototype (Ancestral), Beta, Delta, and/or Omicron BA.1 or BA.4/5] in the COVAIL trial (NCT05289037), titers against 5 strains were assessed as correlates of risk of symptomatic COVID-19 (“COVID-19”) and as correlates of relative (Pfizer-BioNTech Omicron vs. Prototype) booster protection against COVID-19 over 6 months of follow-up during the BA.2-BA.5 Omicron-dominant period. …”
    Get full text
    Article
  4. 124

    Traditional Chinese acupuncture versus minimal acupuncture for mild-to-moderate knee osteoarthritis: a protocol for a randomised, controlled pilot trial by Guang-Xia Shi, Cun-Zhi Liu, Ning Sun, Yi Du, Jian-Feng Tu, Yong-Ting Li, Li-Wen Zhang, Yan Cao, Jing-Jie Zhao, Da-Chang Xiong, Hai-Kun Hou

    Published 2016-12-01
    “…Secondary end points include pain and function measurement, global change, the quality of life and the use of non-steroidal anti-inflammatory drugs (Celebrex, Pfizer) at 8, 16 and 26 weeks.Ethics and dissemination Ethical approval of this study has been granted by the Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (permission number: 2016BL-010-02). …”
    Get full text
    Article
  5. 125

    Papel del Estado en la campaña de vacunación contra la COVID-19 a través del ordenamiento jurídico by Rodolfo Arevalo Marcos, Yolanda Maria Siguas Astorga, Marcos Antonio Montoro Valdivia, José Luis Salazar Huarote

    Published 2024-04-01
    “…Durante el proceso de emergencia, las vacunas que aprobaron las autoridades para la población fueron las Pfizer-BioNTech, Moderna, Sputnik, Jhonson & Jhonson, AstraZeneca, Sinopharm, Sinovac, Covaxin y Covocax. …”
    Get full text
    Article
  6. 126

    COVID-19 Recombinant mRNA Vaccines and Serious Ocular Inflammatory Side Effects: Real or Coincidence? by Arash Maleki, Sydney Look-Why, Ambika Manhapra, C. Stephen Foster

    Published 2021-07-01
    “…Case Reports: The first patient was a 79-year-old female was presented to us 35 days after a sudden bilateral loss of vision, which occurred two days after receiving the second recombinant mRNA vaccine (Pfizer) injection. Temporal artery biopsy was compatible with AAION. …”
    Get full text
    Article
  7. 127
  8. 128
  9. 129

    The effect of meningococcal vaccines on new generation of systemic inflammatory markers in children by Omer Okuyan, Neval Elgormus, Seyma Dumur, Ugurcan Sayili, Hafize Uzun

    Published 2025-01-01
    “…The data of those who received the first 2 doses at 2-month intervals and the next dose between 8–12 months were included. Nimenrix® (Pfizer) administered as a single dose to children from 12 months of age. …”
    Get full text
    Article
  10. 130
  11. 131

    A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus by Min Lin, Yifan Yin, Xiaomeng Zhao, Chen Wang, Xueqing Zhu, Letao Zhan, Li Chen, Siling Wang, Xue Lin, Jun Zhang, Ningshao Xia, Zizheng Zheng

    Published 2025-02-01
    “…Abstract The Food and Drug Administration (FDA) has approved vaccines designed by GSK, Pfizer and Moderna to protect high-risk populations against respiratory syncytial virus (RSV). …”
    Get full text
    Article
  12. 132
  13. 133

    Estudio de reactogenicidad en las vacunas mRNA frente a la COVID-19 by Joan Inglés Torruella, Rosa Maria Gil Soto, Esther Sabaté Aguila, Mercé García Grau, Nina Pons Boronat, Adelaida Rubio Civit, Miriam Bandera Baez, Gustavo Moreno Martin

    Published 2023-04-01
    “… Objetivo: Comparar la reactogenicidad entre los tipos de vacuna RNAm Commirnaty® (Pfizer) y Spikevax® (Moderna) frente a la COVID-19 en población sanitaria. …”
    Get full text
    Article
  14. 134
  15. 135

    Estudio de reactogenicidad en las vacunas mRNA frente a la COVID-19 by Joan Inglés Torruella, Rosa Maria Gil Soto, Esther Sabaté Aguila, Mercé García Grau, Nina Pons Boronat, Adelaida Rubio Civit, Miriam Bandera Baez, Gustavo Moreno Martin

    Published 2023-04-01
    “… Objetivo: Comparar la reactogenicidad entre los tipos de vacuna RNAm Commirnaty® (Pfizer) y Spikevax® (Moderna) frente a la COVID-19 en población sanitaria. …”
    Get full text
    Article
  16. 136

    S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines by Yong-Sik Bong, David Brown, Ezra Chung, Neeti Ananthaswamy, Renxiang Chen, Renxiang Chen, Evan Lewoczko, William Sabbers, Athéna C. Patterson-Orazem, Zachary Dorsey, Yiqing Zou, Xue Yu, Jiening Liang, Jiaxi He, Steven Long, Dong Shen

    Published 2025-01-01
    “…Additionally, the effectiveness of RV-1730 as a heterologous booster following primary vaccination with BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna-NIAID) was assessed.ResultsRV-1730 elicited significantly stronger B and T cell responses and more durable neutralizing antibodies compared to S2P-based vaccines. …”
    Get full text
    Article
  17. 137
  18. 138

    Seroprevalence against SARS-CoV-2 after booster vaccination in a prison in Alicante (Spain) by Ana C. Montagud, Raul Moragues, Nancy Vicente-Alcalde, Nancy Vicente-Alcalde, Emilia Montagud, José Antonio Hurtado-Sánchez, José Antonio Hurtado-Sánchez, José Tuells, José Tuells

    Published 2025-01-01
    “…The vaccines administered in the last dose were Biontech/Pfizer and Moderna in 88.6% of the cases. 59.5% of sample had suffered from COVID-19 and 67.0% did not have any clinical comorbidity. …”
    Get full text
    Article
  19. 139

    Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination by Maaweya Awadalla, Halah Z. AlRawi, Rahaf A. Henawi, Fawziya Barnawi, Haitham Alkadi, Ahmed Alyami, Ammar Alsughayir, Alyazeed S. Alsaif, Ayman Mubarak, Wael Alturaiki, Bandar Alosaimi

    Published 2025-01-01
    “…IntroductionThe durability of Hybrid immunity induced by natural infection and/or COVID-19 vaccines and evidence supporting further booster vaccination are crucial factors for pandemic response, yet remain poorly understood.MethodsWe measured the durability of immune response and neutralizing capacity of antibodies following Homologous/Heterologous vaccination by mRNA-based vaccines (Pfizer-BioNTech BNT162b2) or (Moderna mRNA-1273) and viral vector-based vaccines (ChAdox1 nCoV-19-Oxford-AstraZeneca) in infected and non-infected patients. …”
    Get full text
    Article
  20. 140